Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Senti Biosciences, Inc. (SNTI)
USD0.58
-0.38 (-39.71%)
US NASDAQ Healthcare Biotechnology
Address
2 Corporate Drive 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Timothy K. Lu
Website
sentibio.com
IPO
2021-05-26
CIK 1854270 ISIN US8169441024
Description
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selectively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Dynamics Special Purpose Corp. | DYNS | 2022-02-14 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.58
-0.38 (-39.71%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
198.4K
Beta
2.05
Float Shares
8.09M
Free Float %
30.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +8.00% | +2.97% | +12.03% | +25.00% | -35.40% | +0.00% | -67.60% | -89.28% | -98.96% | -98.96% | -98.96% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (4 ratings, all time)
Buy
Price Targets & DCF
Current price
0.58
Low
6.00
+928.6%
Consensus
6.00
+928.6%
Median
6.00
+928.6%
High
6.00
+928.6%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | 1 |
6.00
+928.6%
|
| All Time | 1 |
6.00
+928.6%
|
Quality scores
Altman Z-Score
-17.39
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+76.2% ★ Q1'26: +95.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-257,845.5%
-
EBIT margin Biotechnology: +0.0%-289,668.2%
-
ROIC Biotechnology: -16.1%-352.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4,792.0% Q1'26: +573.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.48× Q1'26: -1.04× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.29M
est: 5.37M (-38.8%)
|
1.98M
est: 3.46M (-42.8%)
|
—
est: 2.80M (-100.0%)
|
22.0K
est: 1.00M (-97.8%)
|
2.50M
2.50M – 2.50M
+150.0% YoY
|
12.7K
12.7K – 12.7K
-99.5% YoY
|
20.50M
20.50M – 20.50M
+161,635.7% YoY
|
56.75M
56.75M – 56.75M
+176.8% YoY
|
157.40M
157.40M – 157.40M
+177.4% YoY
|
| EBITDA |
-58.16M
est: -3.22M (-1,706.3%)
|
-61.34M
est: -2.08M (-2,853.7%)
|
-54.88M
est: -1.68M (-3,166.4%)
|
-60.09M
est: -600.0K (-9,915.0%)
|
-1.50M
-1.50M – -1.50M
-150.0% YoY
|
-7.6K
-7.6K – -7.6K
+99.5% YoY
|
-12.30M
-12.30M – -12.30M
-161,635.7% YoY
|
-34.05M
-34.05M – -34.05M
-176.8% YoY
|
-94.44M
-94.44M – -94.44M
-177.4% YoY
|
| EBIT |
-62.08M
est: -3.22M (-1,828.1%)
|
-66.77M
est: -2.08M (-3,115.1%)
|
-60.73M
est: -1.68M (-3,514.6%)
|
-63.73M
est: -600.0K (-10,521.2%)
|
-1.50M
-1.50M – -1.50M
-150.0% YoY
|
-7.6K
-7.6K – -7.6K
+99.5% YoY
|
-12.30M
-12.30M – -12.30M
-161,635.7% YoY
|
-34.05M
-34.05M – -34.05M
-176.8% YoY
|
-94.44M
-94.44M – -94.44M
-177.4% YoY
|
| Net Income |
-58.21M
est: -81.92M (+28.9%)
|
-71.06M
est: -77.59M (+8.4%)
|
-52.79M
est: -3.27B (+98.4%)
|
-61.44M
est: -564.84M (+89.1%)
|
-245.82M
-329.35M – -162.29M
+56.5% YoY
|
-201.23M
-201.23M – -201.23M
+18.1% YoY
|
-114.63M
-444.18M – -87.93M
+43.0% YoY
|
-225.96M
-225.96M – -225.96M
-97.1% YoY
|
32.60M
32.60M – 32.60M
+114.4% YoY
|
| SGA |
37.63M
est: 67.59M (-44.3%)
|
34.87M
est: 43.59M (-20.0%)
|
23.51M
est: 688.01M (-96.6%)
|
26.16M
est: 245.72M (-89.4%)
|
614.29M
614.29M – 614.29M
+150.0% YoY
|
3.11M
3.11M – 3.11M
-99.5% YoY
|
5.04B
5.04B – 5.04B
+161,635.7% YoY
|
13.94B
13.94B – 13.94B
+176.8% YoY
|
38.68B
38.68B – 38.68B
+177.4% YoY
|
| EPS |
-13.25
est: -17.83 (+25.7%)
|
-20.94
est: -17.50 (-19.7%)
|
-11.49
est: -14.54 (+21.0%)
|
-2.73
est: -2.65 (-3.2%)
|
-1.09
-1.46 – -0.72
+58.7% YoY
|
-0.90
-0.90 – -0.90
+18.1% YoY
|
-1.18
-1.98 – -0.39
-31.8% YoY
|
-1.01
-1.01 – -1.01
+14.8% YoY
|
0.15
0.15 – 0.15
+114.4% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-43.44M
OE per share TTM
-4.23
Owner's Yield
-189.44%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
2,999.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
357.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
41
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Bayer Aktiengesellschaft | 5.88M | 13.40% | — | — | — | 5.88M | HC, CO | Citizenship or Place of Organization | 2023-02-13 | ↗ |
| 2 | Bayer HealthCare LLC | 5.88M | 13.40% | — | — | — | 5.88M | CO | Citizenship or Place of Organization | 2023-02-13 | ↗ |
| 3 | Bayer US Holding LP | 5.88M | 13.40% | — | — | — | 5.88M | PN | Citizenship or Place of Organization | 2023-02-13 | ↗ |
| 4 | Bayer World Investments B.V. | 5.88M | 13.40% | — | — | — | 5.88M | CO | Citizenship or Place of Organization | 2023-02-13 | ↗ |
| 5 | 15 GP, LLC | 4.43M | 10.10% | — | 4.43M | — | 4.43M | OO | Delaware Limited Liability Company | 2022-07-15 | ↗ |
| 6 | Anthony A. Florence, Jr. | 4.43M | 10.10% | — | 4.43M | — | 4.43M | IN | States | 2022-07-15 | ↗ |
| 7 | Baskett | 4.43M | 10.10% | — | 4.43M | — | 4.43M | IN | States | 2022-07-15 | ↗ |
| 8 | Mohamad H. Makhzoumi | 4.43M | 10.10% | — | 4.43M | — | 4.43M | IN | States | 2022-07-15 | ↗ |
| 9 | NEA Partners 15, L.P. | 4.43M | 10.10% | — | 4.43M | — | 4.43M | PN | Delaware Limited Partnership | 2022-07-15 | ↗ |
| 10 | New Enterprise Associates 15, L.P. | 4.43M | 10.10% | — | 4.43M | — | 4.43M | PN | Delaware Limited Partnership | 2022-07-15 | ↗ |
| 11 | Peter W. Sonsini | 4.43M | 10.10% | — | 4.43M | — | 4.43M | IN | States | 2022-07-15 | ↗ |
| 12 | Scott D. Sandell | 4.43M | 10.10% | — | 4.43M | — | 4.43M | IN | States | 2022-07-15 | ↗ |
| 13 | 52-0556948 | 3.55M | 8.10% | 552.9K | — | 3.23M | — | IA | Maryland | 2023-02-14 | ↗ |
| 14 | Morgan Stanley Investment Management Inc. | 2.89M | 12.20% | — | 2.89M | — | 2.89M | IA, CO | Delaware. | 2022-02-10 | ↗ |
| 15 | 8VC GP I, LLC | 2.54M | 5.80% | — | 2.54M | — | 2.54M | OO | — | 2023-02-08 | ↗ |
| 16 | Joe Lonsdale | 2.54M | 5.80% | 2.54M | — | 2.54M | — | IN | — | 2023-02-08 | ↗ |
| 17 | 8VC Fund I, L.P. | 2.50M | 5.70% | — | 2.50M | — | 2.50M | PN | — | 2023-02-08 | ↗ |
| 18 | ARK Investment Management LLC | 2.38M | 10.03% | 2.38M | — | 2.38M | — | IA | Delaware, United States | 2021-09-10 | ↗ |
| 19 | Woodline Partners LP | 2.00M | 8.40% | 2.00M | — | 2.00M | — | IA | Delaware | 2022-02-11 | ↗ |
| 20 | 1,540,293 | 1.54M | 6.49% | — | 1.54M | — | 1.54M | CO | Delaware | 2022-02-11 | ↗ |
| 21 | Sculptor Capital Holding Corp. | 1.54M | 6.48% | — | 1.54M | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 22 | Sculptor Capital Holding II LLC | 1.54M | 6.48% | — | 1.54M | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 23 | Sculptor Capital II LP | 1.54M | 6.48% | — | 1.54M | — | — | IA | Delaware | 2021-12-29 | ↗ |
| 24 | Sculptor Capital LP | 1.54M | 6.48% | — | 1.54M | — | — | IA | Delaware | 2021-12-29 | ↗ |
| 25 | Sculptor Capital Management, Inc. | 1.54M | 6.48% | — | 1.54M | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 26 | JPMORGAN CHASE & CO.13-2624428 | 1.33M | 5.50% | 1.33M | — | 1.33M | — | HC | Delaware | 2022-02-03 | ↗ |
| 27 | Sculptor SC II LP | 684.1K | 2.88% | — | 684.1K | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 28 | (10) | 547.8K | 2.31% | — | 547.8K | — | 547.8K | CO | Delaware | 2022-02-11 | ↗ |
| 29 | Sculptor Master Fund, Ltd. | 546.8K | 2.31% | — | 546.8K | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 30 | Sculptor Special Funding, LP | 546.8K | 2.31% | — | 546.8K | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 31 | Morgan Stanley | 249.9K | 0.60% | — | 249.9K | — | 249.9K | HC, CO | Delaware. | 2023-02-09 | ↗ |
| 32 | Morgan Stanley Invesment Management Inc. | 249.9K | 0.60% | — | 249.9K | — | 249.9K | IA, CO | Delaware. | 2023-02-09 | ↗ |
| 33 | 163,471 | 163.5K | 0.69% | — | 163.5K | — | 163.5K | CO | Delaware | 2022-02-11 | ↗ |
| 34 | Sculptor Credit Opportunities Master Fund, Ltd. | 163.2K | 0.69% | — | 163.2K | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 35 | MORGAN STANLEY INSTITUTIONAL FUND, INC. INCEPTION PORTFOLIO | 144.6K | 0.30% | — | 144.6K | — | 144.6K | IV | Delaware. | 2023-02-09 | ↗ |
| 36 | 0.61% | 143.6K | 0.61% | — | 143.6K | — | 143.6K | CO | Delaware | 2022-02-11 | ↗ |
| 37 | Sculptor Enhanced Master Fund, Ltd. | 143.3K | 0.60% | — | 143.3K | — | — | CO | Delaware | 2021-12-29 | ↗ |
| 38 | 8VC Entrepreneurs Fund I, L.P. | 39.3K | 0.10% | — | 39.3K | — | 39.3K | PN | — | 2023-02-08 | ↗ |
| 39 | Jeremy C. Green | — | 0.00% | — | — | — | — | HC, IN | United Kingdom | 2022-02-14 | ↗ |
| 40 | Redmile Capital Offshore Master Fund, Ltd. | — | 0.00% | — | — | — | — | FI, CO | Cayman Islands | 2022-02-14 | ↗ |
| 41 | Redmile Group, LLC | — | 0.00% | — | — | — | — | IA, OO | Delaware | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q3
Investors holding
1
+0 vs prev Q
New positions
0
Closed positions
0
Increased
0
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | 8VC GP I, LLC | — -253.8K (-100.0%) | — -357.8K (-100.0%) | 0.00% -0.973 pp | 0.00% -0.460 pp | USD— | 9 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 156.8K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 743.85 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 2.0K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 150.86 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 349.1K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 765.47 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 416.27 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 168.37 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 18.55 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 2.60 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
4
Shares acquired
—
Shares disposed
97.0K
Cash buys
—
Cash sales
—
Net activity
-96,998
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-09 | Rajangam Kanya | Officer | F-InKind | D | Common Stock | 10,757 | 0.00 | — | 74,843 | D | ↗ |
| 2026-03-09 | Lu Timothy K | Director / Officer | F-InKind | D | Common Stock | 80,666 | 0.00 | — | 639,583 | D | ↗ |
| 2026-02-02 | Rajangam Kanya | Officer | F-InKind | D | Common Stock | 1,384 | 0.00 | — | 85,600 | D | ↗ |
| 2026-02-02 | Lu Timothy K | Director / Officer | F-InKind | D | Common Stock | 4,191 | 0.00 | — | 720,249 | D | ↗ |
| 2025-07-18 | Baum Bryan Daniel | Director | A-Award | A | Stock Option (Right to Buy) | 43,900 | 1.95 | 85.6K | 43,900 | D | ↗ |
| 2025-06-25 | Tang Donald F | Director | A-Award | A | Stock Option (Right to Buy) | 21,950 | 2.05 | 45.0K | 21,950 | D | ↗ |
| 2025-06-25 | Schulz Fran | Director | A-Award | A | Stock Option (Right to Buy) | 21,950 | 2.05 | 45.0K | 21,950 | D | ↗ |
| 2025-06-25 | Mathers Edward T | Director | A-Award | A | Stock Option (Right to Buy) | 21,950 | 2.05 | 45.0K | 21,950 | D | ↗ |
| 2025-06-25 | Hsiung Feng | Director | A-Award | A | Stock Option (Right to Buy) | 21,950 | 2.05 | 45.0K | 21,950 | D | ↗ |
| 2025-06-25 | Collins James J. | Director | A-Award | A | Stock Option (Right to Buy) | 21,950 | 2.05 | 45.0K | 21,950 | D | ↗ |
| 2025-06-25 | COOPERSTONE BRENDA | Director | A-Award | A | Stock Option (Right to Buy) | 21,950 | 2.05 | 45.0K | 21,950 | D | ↗ |
| 2025-03-10 | Rajangam Kanya | Officer | C-Conversion | A | Common Stock | 33,000 | 2.25 | 74.3K | 33,000 | I | ↗ |
| 2025-03-10 | New Enterprise Associates 15, L.P. | 10% Owner | C-Conversion | A | Common Stock | 3,333,000 | 0.00 | — | 3,775,615 | D | ↗ |
| 2025-03-10 | Celadon Partners SPV 24 | 10% Owner | C-Conversion | A | Common Stock | 9,777,000 | 0.00 | — | 9,777,000 | D | ↗ |
| 2025-03-10 | BAYER HEALTHCARE LLC | 10% Owner | C-Conversion | D | Series A Convertible Preferred Stock | 2,222 | 0.00 | — | 0 | D | ↗ |
| 2025-03-07 | Tang Donald F | Director | A-Award | A | Stock Option (Right to Buy) | 43,900 | 3.52 | 154.5K | 43,900 | D | ↗ |
| 2025-03-07 | Schulz Fran | Director | A-Award | A | Stock Option (Right to Buy) | 43,900 | 3.52 | 154.5K | 43,900 | D | ↗ |
| 2025-03-07 | Rajangam Kanya | Officer | A-Award | A | Common Stock | 78,363 | 0.00 | — | 86,984 | D | ↗ |
| 2025-03-07 | Mathers Edward T | Director | A-Award | A | Stock Option (Right to Buy) | 43,900 | 3.52 | 154.5K | 43,900 | D | ↗ |
| 2025-03-07 | Lu Timothy K | Director / Officer | A-Award | A | Common Stock | 642,358 | 0.00 | — | 724,440 | D | ↗ |
| 2025-03-07 | Hsiung Feng | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-03-07 | Cross John Harry III | Officer | A-Award | A | Stock Option (Right to Buy) | 174,200 | 3.52 | 613.2K | 174,200 | D | ↗ |
| 2025-03-07 | Collins James J. | Director | A-Award | A | Stock Option (Right to Buy) | 43,900 | 3.52 | 154.5K | 43,900 | D | ↗ |
| 2025-03-07 | COOPERSTONE BRENDA | Director | A-Award | A | Stock Option (Right to Buy) | 43,900 | 3.52 | 154.5K | 43,900 | D | ↗ |
| 2025-03-06 | Rajangam Kanya | Officer | A-Award | A | Stock Option (Right to Buy) | 235,088 | 3.97 | 933.3K | 235,088 | D | ↗ |
| 2025-03-06 | New Enterprise Associates 15, L.P. | 10% Owner | — | — | Earnout Rights (Common Stock) | 13,711 | 0.00 | — | 0 | D | ↗ |
| 2025-03-06 | Lu Timothy K | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,927,073 | 3.97 | 7.65M | 1,927,073 | D | ↗ |
| 2025-03-06 | Celadon Partners SPV 24 | 10% Owner | — | — | Series A Convertible Preferred Stock | 9,777,000 | 2.25 | 22.00M | 0 | D | ↗ |
| 2025-03-03 | Cross John Harry III | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-02-06 | Rajangam Kanya | Officer | S-Sale | D | Common Stock | 182 | 4.37 | 795.34 | 8,621 | D | ↗ |
| 2025-02-06 | Lu Timothy K | Director / Officer | S-Sale | D | Common Stock | 545 | 4.36 | 2.4K | 82,082 | D | ↗ |
| 2025-02-04 | Rajangam Kanya | Officer | S-Sale | D | Common Stock | 1,297 | 4.07 | 5.3K | 8,803 | D | ↗ |
| 2025-02-04 | Lu Timothy K | Director / Officer | S-Sale | D | Common Stock | 3,922 | 4.07 | 16.0K | 82,627 | D | ↗ |
| 2024-12-09 | Tang Donald F | Director | — | — | Common Stock | 0 | 0.00 | — | 10,368 | D | ↗ |
| 2024-12-09 | Schulz Fran | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-09 | Rajangam Kanya | Officer | A-Award | A | Series A Convertible Preferred Stock | 33 | 2.25 | 74.25 | 33 | I | ↗ |
| 2024-12-09 | BAYER HEALTHCARE LLC | 10% Owner | P-Purchase | A | Series A Convertible Preferred Stock | 2,222 | 0.00 | — | 2,222 | D | ↗ |
| 2024-07-10 | Mathers Edward T | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.31 | 19.4K | 62,500 | — | ↗ |
| 2024-07-10 | Farokhzad Omid | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.31 | 19.4K | 62,500 | — | ↗ |
| 2024-07-10 | Collins James J. | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.31 | 19.4K | 62,500 | — | ↗ |
| 2024-07-10 | COOPERSTONE BRENDA | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.31 | 19.4K | 62,500 | — | ↗ |
| 2024-05-04 | Li Yvonne | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-02-01 | Rajangam Kanya | Officer | A-Award | A | Stock Option (Right to Buy) | 152,000 | 0.46 | 69.9K | 152,000 | — | ↗ |
| 2024-02-01 | Lu Timothy K | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 459,000 | 0.46 | 211.1K | 459,000 | — | ↗ |
| 2024-02-01 | KNOBELMAN DEBORAH | Officer | A-Award | A | Common Stock | 101,000 | 0.00 | — | 131,000 | — | ↗ |
| 2023-06-16 | Mathers Edward T | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.99 | 61.9K | 62,500 | — | ↗ |
| 2023-06-16 | Farokhzad Omid | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.99 | 61.9K | 62,500 | — | ↗ |
| 2023-06-16 | Collins James J. | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.99 | 61.9K | 62,500 | — | ↗ |
| 2023-06-16 | COOPERSTONE BRENDA | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.99 | 61.9K | 62,500 | — | ↗ |
| 2023-06-16 | Berland Susan D | Director | A-Award | A | Stock Option (Right to Buy) | 62,500 | 0.99 | 61.9K | 62,500 | — | ↗ |
| 2023-02-01 | Rajangam Kanya | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 1.81 | 235.3K | 130,000 | — | ↗ |
| 2023-02-01 | Lu Timothy K | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 630,000 | 1.81 | 1.14M | 630,000 | — | ↗ |
| 2023-02-01 | Lee Philip J | Officer | A-Award | A | Stock Option (Right to Buy) | 195,000 | 1.81 | 353.0K | 195,000 | — | ↗ |
| 2023-02-01 | KNOBELMAN DEBORAH | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 1.81 | 235.3K | 130,000 | — | ↗ |
| 2022-10-03 | KNOBELMAN DEBORAH | Officer | A-Award | A | Stock Option (Right to Buy) | 240,000 | 0.00 | — | 240,000 | — | ↗ |
| 2022-07-18 | Rajangam Kanya | Officer | A-Award | A | Stock Option (Right to Buy) | 327,750 | 1.80 | 590.0K | 327,750 | — | ↗ |
| 2022-07-13 | Mathers Edward T | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-07-13 | Farokhzad Omid | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-07-13 | Epstein David R | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-07-13 | Collins James J. | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 1.75 | 218.8K | 125,000 | — | ↗ |
| 2022-07-13 | COOPERSTONE BRENDA | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-07-13 | Berland Susan D | Director | A-Award | A | Stock Option (Right to Buy) | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-07-05 | Rajangam Kanya | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-08 | New Enterprise Associates 15, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,426,151 | — | ↗ |
| 2022-06-08 | Mathers Edward T | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-08 | Lu Timothy K | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 528,390 | — | ↗ |
| 2022-06-08 | Lee Philip J | Officer | — | D | Common Stock | 0 | 0.00 | — | 936,424 | — | ↗ |
| 2022-06-08 | KNOBELMAN DEBORAH | Officer | — | D | Stock Option (Right to Buy) | 146,775 | 7.87 | 1.16M | 0 | — | ↗ |
| 2022-06-08 | Herberts Curt A. III | Officer | — | I | Earnout Rights (Common Stock) | 19,603 | 0.00 | — | 0 | — | ↗ |
| 2022-06-08 | Farokhzad Omid | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-08 | Epstein David R | Director | A-Award | A | Common Stock | 112,519 | 0.00 | — | 123,252 | — | ↗ |
| 2022-06-08 | Dynamics Sponsor LLC | Director | J-Other | D | Common Stock | 6,465,500 | 0.00 | — | 0 | — | ↗ |
| 2022-06-08 | Collins James J. | Director | — | D | Common Stock | 0 | 0.00 | — | 176,130 | — | ↗ |
| 2022-06-08 | COOPERSTONE BRENDA | Director | — | D | Stock Option (Right to Buy) | 31,438 | 3.12 | 98.1K | 0 | — | ↗ |
| 2022-06-08 | Berland Susan D | Director | — | D | Stock Option (Right to Buy) | 17,613 | 7.87 | 138.6K | 0 | — | ↗ |
| 2022-06-08 | BAYER HEALTHCARE LLC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 5,878,488 | — | ↗ |
| 2021-05-25 | Ronaghi Mostafa | Director / Officer | — | I | Class B common stock | 5,750,000 | 0.00 | — | 0 | — | ↗ |
| 2021-05-25 | Nishar Dipchand | Director | — | I | Class B common stock | 112,519 | 0.00 | — | 0 | — | ↗ |
| 2021-05-25 | Farokhzad Omid | Director | — | I | Class A common stock | 0 | 0.00 | — | 715,500 | — | ↗ |
| 2021-05-25 | FLATLEY JAY T | Director | — | I | Class B common stock | 112,519 | 0.00 | — | 0 | — | ↗ |
| 2021-05-25 | Epstein David R | Director | — | I | Class A common stock | 0 | 0.00 | — | 10,733 | — | ↗ |
| 2021-05-25 | Dynamics Sponsor LLC | 10% Owner | — | D | Class B common stock | 5,750,000 | 0.00 | — | 0 | — | ↗ |
| 2021-05-25 | Chapman Rowan E | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-05-25 | Afrasiabi Mark | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-06-25 | MARTELL RON | Director / Officer | A-Award | A | Employee Stock Option | 400,000 | 2.66 | 1.06M | 400,000 | — | ↗ |
| 2014-06-13 | FROST PHILLIP MD ET AL | Director / 10% Owner | A-Award | A | Series A Warrants | 333,333 | 3.00 | 1,000.0K | 333,333 | — | ↗ |
| 2014-05-16 | Rubin Steven D | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-05-16 | RIOS MIGUEL DE LOS | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2014-05-16 | FROST PHILLIP MD ET AL | Director / 10% Owner | A-Award | A | Warrant | 646 | 2.00 | 1.3K | 646 | — | ↗ |
| 2014-05-14 | Waksal Harlan | Director | A-Award | A | Common Stock Option | 21,932 | 2.77 | 60.8K | 54,298 | — | ↗ |
| 2014-05-14 | RECTOR DAVID | Director | A-Award | A | Common Stock Option | 21,074 | 2.77 | 58.4K | 41,682 | — | ↗ |
| 2014-05-14 | FORBES CHRISTOPHER | Director | A-Award | A | Common Stock Option | 17,464 | 2.77 | 48.4K | 36,406 | — | ↗ |
| 2014-05-14 | BRACA JOHN N | Director | A-Award | A | Common Stock Option | 21,074 | 2.77 | 58.4K | 40,946 | — | ↗ |
| 2013-12-19 | Browne Leslie J | Director / Officer | P-Purchase | A | Common Stock | 800 | 4.15 | 3.3K | 1,290 | — | ↗ |
| 2013-12-16 | FROST PHILLIP MD ET AL | Director / 10% Owner | — | I | Warrants | 333,333 | 4.00 | 1.33M | 0 | — | ↗ |
| 2013-09-13 | Waksal Harlan | Director | A-Award | A | Common Stock Option | 530,000 | 0.05 | 28.6K | 3,236,572 | — | ↗ |
| 2013-09-13 | THOMPSON JOHN PHD | Director / Officer | A-Award | A | Common Stock Option | 985,000 | 0.05 | 53.2K | 2,203,276 | — | ↗ |
| 2013-09-13 | RECTOR DAVID | Director | A-Award | A | Common Stock Option | 371,000 | 0.05 | 20.0K | 2,080,765 | — | ↗ |
| 2013-09-13 | FORBES CHRISTOPHER | Director | A-Award | A | Common Stock Option | 318,000 | 0.05 | 17.2K | 2,002,193 | — | ↗ |
| 2013-09-13 | Dondero Richard S | Officer | A-Award | A | Common Stock Option | 985,000 | 0.05 | 53.2K | 2,360,124 | — | ↗ |
| 2013-09-13 | Browne Leslie J | Director / Officer | A-Award | A | Common Stock Option | 1,723,000 | 0.05 | 93.0K | 4,157,800 | — | ↗ |
| 2013-09-13 | BRACA JOHN N | Director | A-Award | A | Common Stock Option | 371,000 | 0.05 | 20.0K | 1,992,215 | — | ↗ |
| 2013-05-20 | Browne Leslie J | Director / Officer | P-Purchase | A | Common Stock | 30,000 | 0.04 | 1.2K | 49,000 | — | ↗ |
| 2013-05-17 | Waksal Harlan | Director | A-Award | A | Common Stock Option | 273,256 | 0.04 | 11.8K | 2,716,572 | — | ↗ |
| 2013-05-17 | RECTOR DAVID | Director | A-Award | A | Common Stock Option | 244,186 | 0.04 | 10.5K | 1,704,765 | — | ↗ |
| 2013-05-17 | FORBES CHRISTOPHER | Director | A-Award | A | Common Stock Option | 238,372 | 0.04 | 10.2K | 1,684,193 | — | ↗ |
| 2013-05-17 | BRACA JOHN N | Director | A-Award | A | Common Stock Option | 139,534 | 0.04 | 6.0K | 1,621,215 | — | ↗ |
| 2013-02-19 | Waksal Harlan | Director | A-Award | A | Common Stock Option | 145,834 | 0.13 | 19.3K | 2,433,316 | — | ↗ |
| 2013-02-19 | RECTOR DAVID | Director | A-Award | A | Common Stock Options | 96,590 | 0.13 | 12.7K | 1,460,579 | — | ↗ |
| 2013-02-19 | FORBES CHRISTOPHER | Director / 10% Owner | A-Award | A | Common Stock Option | 89,016 | 0.15 | 13.4K | 1,495,821 | — | ↗ |
| 2013-02-19 | BRACA JOHN N | Director | A-Award | A | Common Stock Option | 56,818 | 0.13 | 7.5K | 1,481,681 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-18.7K
Shares Outstanding
26.29M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Timothy Lu, M.D., Ph.D. Chief Executive Officer | 618.8K | — | 140.8K | 159.1K | 442.4K | 12.0K | 930.7K | 32.22% | ↗ |
| 2 | 2024 | Kanya Rajangam, M.D., Ph.D. President, Head of Research and Development and Chief Medical Officer | 526.8K | — | 46.5K | 52.7K | 265.5K | 1.8K | 858.8K | 11.55% | ↗ |
| 3 | 2024 | Yvonne Li, Interim Chief Financial Officer | — | — | — | — | — | 547.5K | 547.5K | 0.00% | ↗ |
| 4 | 2024 | Yvonne Li Former Chief Financial Officer | — | — | — | — | — | 547.5K | 547.5K | 0.00% | ↗ |
| 5 | 2023 | Timothy Lu, M.D., Ph.D. Chief Executive Officer | 606.6K | — | — | 817.9K | 250.2K | 11.7K | 1.69M | 48.50% | ↗ |
| 6 | 2023 | Deborah Knobelman, Ph.D. Former Chief Financial Officer, Treasurer and Head of Corporate Development | 460.0K | — | — | 168.8K | 154.6K | 6.3K | 789.7K | 21.37% | ↗ |
| 7 | 2023 | Kanya Rajangam, M.D., Ph.D. President, Head of Research and Development and Chief Medical Officer | 516.5K | — | — | 168.8K | 173.5K | — | 627.7K | 26.89% | ↗ |
| 8 | 2022 | Deborah Knobelman, Ph.D. Former Chief Financial Officer, Treasurer and Head of Corporate Development | 425.0K | — | 75.0K | 428.2K | 170.0K | 5.2K | 1.10M | 45.60% | ↗ |
| 9 | 2022 | Deborah Knobelman, Ph.D. Chief Financial Officer, Treasurer and Head of Corporate Development | 425.0K | — | 75.0K | 428.2K | 170.0K | 5.2K | 1.10M | 45.60% | ↗ |
| 10 | 2022 | Kanya Rajangam, M.D., Ph.D. President, Head of Research and Development and Chief Medical Officer | 241.3K | 90.0K | — | 412.7K | 96.5K | — | 840.5K | 49.10% | ↗ |
| 11 | 2022 | Kanya Rajangam, M.D., Ph.D. Head of Research and Development and Chief Medical Officer | 241.3K | 90.0K | — | 412.7K | 96.5K | — | 840.5K | 49.10% | ↗ |
| 12 | 2022 | Timothy Lu, M.D., Ph.D. Chief Executive Officer | 537.6K | — | — | — | 268.8K | 4.8K | 811.3K | 0.00% | ↗ |
| 13 | 2022 | Timothy Lu, M.D.,Ph.D. President and Chief Executive Officer | 537.6K | — | — | — | 268.8K | 4.8K | 811.3K | 0.00% | ↗ |
| 14 | 2021 | Timothy Lu, M.D.,Ph.D. President and Chief Executive Officer | 475.0K | — | — | 23.80M | 219.2K | — | 24.50M | 97.17% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kanya Rajangam | President, Head of Research & Development and Chief Medical Officer | 794.0K | — |
| Timothy K. Lu | Co-Founder, Chief Executive Officer & Director | 630.8K | — |
| James J. Collins | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director | 43.9K | — |
| Robert H. Cutler | Senior Vice President & Head of Legal Affairs | — | male |
| Thomas Chung | Vice President of Strategic Finance & Corporate Development | — | male |
| Dee Olomajeye Dragon | Senior VP of People & Culture Strategy & Head of Administrative Operations | — | female |
| Wilson Wong | Scientific Co-Founder & Member of Scientific Advisory Board | — | — |
| Faraz Siddiqui | Senior Vice President of Technical Operations | — | male |
| Jay Cross | Chief Financial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SNTI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
